Todd Tushla | Vice President, Investor Relations |
Kevin Gorman | Chief Executive Officer and Director |
Matt Abernethy | Chief Financial Officer |
Dr. Eiry Roberts | Chief Medical Officer |
Eric Benevich | Chief Commercial Officer |
Kyle Gano | Chief Business Development and Strategy Officer |
Phil Nadeau | Cowen |
Paul Matteis | Stifel |
Tazeen Ahmad | Bank of America |
Brian Abrahams | RBC Capital Markets |
Anupam Rama | JPMorgan |
Carter Gould | Barclays |
Neena Bitritto-Garg | Citi |
Myles Minter | William Blair |
Joshua Schimmer | Evercore |
David Amsellem | Piper Sandler |
Jay Olson | Oppenheimer |
Vamil Divan | Mizuho Securities |
Marc Goodman | SBC Leerink |
Charles Duncan | Cantor Fitzgerald |
Chris Shibutani | Goldman Sachs |
Evan Seigerman | BMO Capital Markets |
Jeff Hung | Morgan Stanley |
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year-End results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. Please note today's call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations.